Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.

The global Neurodegenerative Diseases market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Neurodegenerative Diseases volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neurodegenerative Diseases market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Neurodegenerative Diseases in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Neurodegenerative Diseases manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
Merck Serono
Teva Pharmaceutical
UCB
Pfizer
Biogen Idec
Bayer Schering Pharma AG
Boehringer Ingelheim
Addex Pharmaceutical
Amarin
AstraZeneca
Asubio Pharmaceutical
Bial
Alector
Yumanity Therapeutics
Eisai
H.Lundbeck A/S
Jiangsu Hansoh Pharmaceutical
Yangtze River Pharmaceutical Group
Chongqing Zein Pharmaceutical

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application
Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease